@article {Gambardella2020.06.16.20133256, author = {Jessica Gambardella and Celestino Sardu and Marco Bruno Morelli and Vincenzo Messina and Vanessa Castellanos and Raffaele Marfella and Paolo Maggi and Giuseppe Paolisso and Xujun Wang and Gaetano Santulli}, title = {Exosomal microRNAs Drive Thrombosis in COVID-19}, elocation-id = {2020.06.16.20133256}, year = {2020}, doi = {10.1101/2020.06.16.20133256}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Thrombotic and thromboembolic complications have been shown to play a critical role in the clinical outcome of COVID-19. Emerging evidence has shown that exosomal miRNAs are functionally involved in a number of physiologic and pathologic processes. However, neither exosomes nor miRNAs have been hitherto investigated in COVID-19. To test the hypothesis that exosomal miRNAs are a key determinant of thrombosis in COVID-19, we enrolled patients positive for COVID-19. Circulating exosomes were isolated from equal amounts of serum and levels of exosomal miRNAs were quantified. We divided our population in two groups based on the serum level of D-dimer on admission. Strikingly, we found that exosomal miR-424 was significantly upregulated whereas exosomal miR-103a, miR-145, and miR-885 were significantly downregulated in patients in the high D-dimer group compared to patients in the low D-Dimer group (p\<0.0001).Competing Interest StatementThe authors have declared no competing interest.Funding Statement-Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Naples University Ethical CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the manuscript}, URL = {https://www.medrxiv.org/content/early/2020/06/18/2020.06.16.20133256}, eprint = {https://www.medrxiv.org/content/early/2020/06/18/2020.06.16.20133256.full.pdf}, journal = {medRxiv} }